---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-054787"
form_type: "8-K"
ticker: "MREO"
cik: "0001719714"
company_name: "Mereo BioPharma Group plc"
filed_at: "2026-02-17T23:59:59+00:00"
generated_at: "2026-05-16T02:28:23.979791+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Mereo Biopharma receives Nasdaq bid price deficiency notice; compliance period through Aug 2026

## Summary
- Received letter on Feb 17, 2026 re: ADS closing bid price below $1.00 for 30 consecutive business days.
- 180-day compliance period until August 17, 2026 to regain minimum bid price requirement.
- To regain compliance, bid price must close at $1.00+ for at least 10 consecutive business days.
- If not compliant by Aug 17, may be eligible for additional 180-day grace period subject to other Nasdaq standards.
- ADSs continue trading under MREO; company states business operations unaffected.

## SEC filing metadata
- accession: 0001193125-26-054787
- form_type: 8-K
- ticker: MREO
- cik: 0001719714
- company_name: Mereo BioPharma Group plc
- filed_at: 2026-02-17T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1719714/000119312526054787/0001193125-26-054787-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1719714/000119312526054787/mreo-20260217.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-054787
- JSON: https://secwatch.observer/filing/0001193125-26-054787.json
- Plain text: https://secwatch.observer/filing/0001193125-26-054787.txt

## Source-grounded claims
- claim_id: 34c920c8231f03412f53bed9a6b31d5fafaace2a
  claim: Mereo BioPharma Group plc received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
  evidence_excerpt: February 17, 2026, Mereo BioPharma Group plc (the “Company”) received a letter (the “Notification Letter”) from the Listings Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that its American Depositary Shares (“ADSs”) failed to maintain a minimum bid price of $1.00 over the previous 30 consecutive business days as required for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Requirement”). The Notification Letter does not result in the immediate delisting of the Company’s ADSs, and the ADSs will contin
  evidence_url: https://www.sec.gov/Archives/edgar/data/1719714/000119312526054787/0001193125-26-054787-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.